Systemic and Central Inflammation in AD - Trial NCT06384378
Access comprehensive clinical trial information for NCT06384378 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Methodist Hospital Research Institute and is currently Recruiting. The study focuses on Alzheimer Disease. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Methodist Hospital Research Institute
Timeline & Enrollment
Phase 2
Mar 17, 2023
Dec 30, 2025
Primary Outcome
Blood inflammation biomarker levels,CSF inflammation biomarker levels,Voxel-wise, regional and total brain TSPO VT/fP measured with 11C-ER176 PET
Summary
Inflammation could provide a new focus for therapeutic intervention. In this study, we will
 measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to
 measurements of brain glial activation obtained by positron emission tomography (PET). In
 addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given
 over 22 weeks, on these inflammation biomarkers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06384378
Non-Device Trial